JP2002511846A - Hsvアンプリコンベクターによる自家腫瘍ワクチンの迅速な産生 - Google Patents
Hsvアンプリコンベクターによる自家腫瘍ワクチンの迅速な産生Info
- Publication number
- JP2002511846A JP2002511846A JP54583098A JP54583098A JP2002511846A JP 2002511846 A JP2002511846 A JP 2002511846A JP 54583098 A JP54583098 A JP 54583098A JP 54583098 A JP54583098 A JP 54583098A JP 2002511846 A JP2002511846 A JP 2002511846A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- amplicon
- tumor
- transduced
- tumor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108091093088 Amplicon Proteins 0.000 title claims abstract description 117
- 238000004519 manufacturing process Methods 0.000 title claims description 18
- 229960005486 vaccine Drugs 0.000 title claims description 16
- 206010028980 Neoplasm Diseases 0.000 title description 96
- 239000013598 vector Substances 0.000 title description 38
- 210000004027 cell Anatomy 0.000 claims abstract description 297
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 137
- 241000700584 Simplexvirus Species 0.000 claims abstract description 86
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 75
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 65
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 53
- 108090000695 Cytokines Proteins 0.000 claims abstract description 33
- 102000004127 Cytokines Human genes 0.000 claims abstract description 29
- 238000001727 in vivo Methods 0.000 claims abstract description 19
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims abstract description 12
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims abstract description 12
- 102000019034 Chemokines Human genes 0.000 claims abstract description 12
- 108010012236 Chemokines Proteins 0.000 claims abstract description 12
- 241000894007 species Species 0.000 claims abstract description 11
- 208000009889 Herpes Simplex Diseases 0.000 claims abstract description 10
- 108010055166 Chemokine CCL5 Proteins 0.000 claims abstract description 8
- 102000001327 Chemokine CCL5 Human genes 0.000 claims abstract description 7
- 230000002463 transducing effect Effects 0.000 claims abstract description 7
- 241001465754 Metazoa Species 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 60
- 108010002350 Interleukin-2 Proteins 0.000 claims description 39
- 102000000588 Interleukin-2 Human genes 0.000 claims description 38
- 208000014018 liver neoplasm Diseases 0.000 claims description 22
- 201000007270 liver cancer Diseases 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 238000010361 transduction Methods 0.000 claims description 18
- 230000026683 transduction Effects 0.000 claims description 18
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 108010065805 Interleukin-12 Proteins 0.000 claims description 7
- 102000013462 Interleukin-12 Human genes 0.000 claims description 7
- 230000010474 transient expression Effects 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 5
- 229940117681 interleukin-12 Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract description 20
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract description 19
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 abstract description 10
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 abstract description 9
- 102000014150 Interferons Human genes 0.000 abstract description 2
- 108010050904 Interferons Proteins 0.000 abstract description 2
- 229940037642 autologous vaccine Drugs 0.000 abstract description 2
- 229940047124 interferons Drugs 0.000 abstract description 2
- 229940047122 interleukins Drugs 0.000 abstract description 2
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 52
- 239000002609 medium Substances 0.000 description 39
- 230000014509 gene expression Effects 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 26
- 238000003556 assay Methods 0.000 description 26
- 238000012546 transfer Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 24
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 24
- 210000004988 splenocyte Anatomy 0.000 description 20
- 230000004614 tumor growth Effects 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 241000700159 Rattus Species 0.000 description 19
- 238000002255 vaccination Methods 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 210000001865 kupffer cell Anatomy 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 230000012010 growth Effects 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
- 239000012228 culture supernatant Substances 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 210000004989 spleen cell Anatomy 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000002476 tumorcidal effect Effects 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 102000005936 beta-Galactosidase Human genes 0.000 description 8
- 108010005774 beta-Galactosidase Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 8
- 230000002269 spontaneous effect Effects 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- -1 ANTES) Proteins 0.000 description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 6
- 108010004729 Phycoerythrin Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000043559 human ICAM1 Human genes 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 229910052693 Europium Inorganic materials 0.000 description 4
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 241001227713 Chiron Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108090000204 Dipeptidase 1 Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000012752 Hepatectomy Methods 0.000 description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 206010064390 Tumour invasion Diseases 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000009400 cancer invasion Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 229940044627 gamma-interferon Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 description 3
- 102000034356 gene-regulatory proteins Human genes 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229920002113 octoxynol Polymers 0.000 description 3
- 238000012753 partial hepatectomy Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000005748 tumor development Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- HFSHGXIPMHQUFT-UHFFFAOYSA-N 3,8-dihydroxy-2-(hydroxymethyl)-7-methylnon-1-en-4-one Chemical compound CC(O)C(C)CCC(=O)C(O)C(=C)CO HFSHGXIPMHQUFT-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 108010040471 CC Chemokines Proteins 0.000 description 2
- 102000001902 CC Chemokines Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 102000044547 Nodal Human genes 0.000 description 2
- 108700024442 Nodal Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002555 ionophore Substances 0.000 description 2
- 230000000236 ionophoric effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NBWRJAOOMGASJP-UHFFFAOYSA-N 2-(3,5-diphenyl-1h-tetrazol-1-ium-2-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1N1N(C=2C=CC=CC=2)N=C(C=2C=CC=CC=2)[NH2+]1 NBWRJAOOMGASJP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000006678 Abdominal Neoplasms Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 102100023701 C-C motif chemokine 18 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 235000009414 Elaeocarpus kirtonii Nutrition 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010454 Experimental Liver Neoplasms Diseases 0.000 description 1
- 101150114877 Ezr gene Proteins 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000765923 Homo sapiens Bcl-2-like protein 1 Proteins 0.000 description 1
- 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 235000013584 Tabebuia pallida Nutrition 0.000 description 1
- 244000236151 Tabebuia pallida Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- CESGKXMBHGUQTB-VONOSFMSSA-N [(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(OC(=O)CCCCCCCCCCCCC)C(C)(C)[C@H]3[C@@H]21 CESGKXMBHGUQTB-VONOSFMSSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000003134 dye exclusion method Methods 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108010015249 protease XXIV Proteins 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940030325 tumor cell vaccine Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.免疫調節タンパク質および治療遺伝子産物を細胞に一過性に発現させるため に、免疫調節タンパク質に対する遺伝子および少なくとも1つのさらなる治療遺 伝子を含む1種以上の単純ヘルペスウイルスアンプリコンを腫瘍細胞に形質導入 することを含む、腫瘍細胞に対する自家ワクチンを産生する方法。 2.腫瘍細胞が単純ヘルペス・アンプリコンによってエクスビボで形質導入され る、請求項1に記載の方法。 3.腫瘍細胞が単純ヘルペス細胞によってインビボで形質導入される請求項1に 記載の方法。 4.免疫調節タンパク質および治療遺伝子産物を細胞に一過性に発現させるため に、免疫調節タンパク質に対する遺伝子および少なくとも1つのさらなる治療遺 伝子を含む、1種以上の単純ヘルペスウイルス・アンプリコンを腫瘍細胞に形質 導入する工程を含む、患者に対して腫瘍細胞に対する保護免疫応答を誘導する方 法。 5.形質導入した腫瘍細胞を患者に導入する工程をさらに含む、腫瘍細胞がエク スビボでアンプリコンによって形質導入される、請求項4に記載の方法。 6.アンプリコンをインビボで腫瘍細胞の部位に注射する、請求項4に記載の方 法。 7.免疫調節タンパク質がサイトカインである、請求項1〜6のいずれかに記載 の方法。 8.サイトカインがインターロイキン-2である、請求項7に記載の方法。 9.サイトカインが顆粒球マクロファージコロニー刺激因子である、請求項7に 記載の方法。 10.免疫調節タンパク質がケモカインである、請求項7に記載の方法。 11.ケモカインがランテス(RANTES)である、請求項10に記載の方法。 12.免疫調節タンパク質が細胞間接着分子である、請求項1〜6のいずれかに記 載の方法。 13.細胞間接着分子がIACM-1である、請求項12に記載の方法。 14.免疫調節タンパク質が共刺激因子である、請求項1〜6のいずれかに記載 の方法。 15.共刺激因子がB7.1である、請求項14に記載の方法。 16.腫瘍細胞の集団が、免疫調節タンパク質に対する遺伝子およびさらなる治療 遺伝子を含む複数の種のアンプリコンによって形質導入される、請求項1〜15の いずれかに記載の方法。 17.さらなる治療遺伝子が第二の免疫調節タンパク質をコードする、請求項1〜 16のいずれかに記載の方法。 18.腫瘍細胞が少なくとも2種のナイトカインをコードして発現するアンプリコ ンによって形質導入される、請求項17記載の方法。 19.腫瘍細胞がインターロイキン-2およびインターロイキン-12に対する遺伝子 を含むアンプリコンによって形質導入される、請求項18に記載の方法。 20.腫瘍細胞が、サイトカインおよび共刺激天子をコードおよび発現するアンプ リコンによって形質導入される、請求項18に記載の方法。 21.腫瘍細胞が、ランテスおよびB7.1に対する遺伝子を含むアンプリコンによっ て形質導入される、請求項20に記載の方法。 22.腫瘍細胞が肝癌細胞またはリンパ腫細胞である、請求項1〜21のいずれかに 記載の方法。 23.少なくとも1つの免疫調節タンパク質に灯する遺伝子を含む第一の種のアン プリコンおよびさらなる治療遺伝子産物に対する遺伝子を含む第二の種のアンプ リコンを含む、複数種の単純ヘルペスウイルスアンプリコンを含む混合物。 24.免疫調節タンパク質がサイトカインである、請求項23に記載の混合物。 25.サイトカインがインターロイキン-2または顆粒球マクロファージコロニー刺 激因子である、請求項24に記載の混合物。 26.免疫調節タンパク質がケモカインである、請求項23に記載の混合物。 27.ケモカインがランテスである、請求項26に記載の混合物。 28.免疫調節タンパク質が細胞間接着分子である、請求項23に記載の混合物。 29.細胞間接着分子がIACM-1である、請求項28に記載の混合物。 30.免疫調節タンパク質が共刺激因子である、請求項23に記載の混合物。 31.共刺激因子がB7.1である、請東項30に記載の混合物。 32.さらなる治療遺伝子が第二の免疫調節タンパク質をコードする、請求項23〜 31のいずれかに記載の混合物。 33.第一および第二の種のアンプリコンがランテスおよびB7.1をコードする遺伝 子を含む、請求項23〜32のいずれかに記載の混合物。 34.第一および第二の種のアンプリコンが少なくとも2種のサイトカインをコー ドする遺伝子を含む、請求項23〜32のいずれかに記載の混合物。 35.アンプリコンがインターロイキン-2およびインターロイキン-12をコードす る遺伝子を含む、請求項34記載の混合物。 36.請求項1〜22のいずれかの方法に従って形質導入された腫瘍細胞。 37.請求項23〜35のいずれかによる単純ヘルペスウイルス・アンプリコンを形質 導入した腫瘍細胞。 38.免疫調節タンパク質がケモカイン、細胞間接着分子、および共刺激因子から 選択される、免疫調節タンパク質を細胞に一過性に発現させるために、免疫調節 タンパク質に対する遺伝子を含む単純ヘルペスウイルス・アンプリコンを腫瘍細 胞に形質導入することを含む、腫瘍細胞に対する自家ワクチンを産生する方法。 39.腫瘍細胞がエクスビボで単純ヘルペスアンプリコンによって形質導入される 、請求項1に記載の方法。 40.腫瘍細胞がインビボで単純ヘルペス細胞によって形質導入される、請求項1 に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4400597P | 1997-03-21 | 1997-03-21 | |
US60/044,005 | 1997-03-21 | ||
PCT/US1998/005505 WO1998042855A1 (en) | 1997-03-21 | 1998-03-20 | Rapid production of autologous tumor vaccines by using hsv amplicon vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002511846A true JP2002511846A (ja) | 2002-04-16 |
Family
ID=21930021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54583098A Ceased JP2002511846A (ja) | 1997-03-21 | 1998-03-20 | Hsvアンプリコンベクターによる自家腫瘍ワクチンの迅速な産生 |
Country Status (6)
Country | Link |
---|---|
US (3) | US6051428A (ja) |
EP (1) | EP0968299A1 (ja) |
JP (1) | JP2002511846A (ja) |
AU (1) | AU7357098A (ja) |
CA (1) | CA2287156A1 (ja) |
WO (1) | WO1998042855A1 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5900245A (en) | 1996-03-22 | 1999-05-04 | Focal, Inc. | Compliant tissue sealants |
US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
US6764675B1 (en) | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
AU6120600A (en) * | 1999-06-08 | 2000-12-28 | Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
US7064111B1 (en) * | 1999-10-05 | 2006-06-20 | Georgetown University | Use of soluble costimulatory factor for tumor immuno-gene therapy |
WO2001053506A2 (en) * | 2000-01-21 | 2001-07-26 | Biovex Limited | Virus strains for the oncolytic treatment of cancer |
CN100542614C (zh) * | 2000-02-02 | 2009-09-23 | 安增子摩祺株式会社 | 用于基因转移的病毒包膜载体 |
AUPQ755300A0 (en) | 2000-05-17 | 2000-06-08 | Monash University | Immune potentiating compositions |
EP1350113A2 (en) | 2000-08-30 | 2003-10-08 | Chemocentryx, Inc. | Inhibition of cmv infection and dissemination |
AU2002220262A1 (en) * | 2000-11-09 | 2002-05-21 | Genetics Institute, Llc | Sdf-1 beta expressing tumor cells as tumor vaccines |
ATE466078T1 (de) * | 2000-11-29 | 2010-05-15 | Univ Rochester | Helfervirus-freie herpesvirus-amplifikatpartikel und deren verwendungen |
DE10290185D2 (de) * | 2001-01-31 | 2004-04-15 | Mologen Forschungs Entwicklung | Tumorvakzine |
WO2002062296A2 (en) * | 2001-02-02 | 2002-08-15 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
US8092791B2 (en) * | 2001-05-23 | 2012-01-10 | University Of Rochester | Method of producing herpes simplex virus amplicons, resulting amplicons, and their use |
CA2466698A1 (en) * | 2001-11-09 | 2003-05-15 | Medigene Aktiengesellschaft | Cellular vaccines comprising adjuvants |
US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US20060171922A1 (en) * | 2002-05-31 | 2006-08-03 | Federoff Howard J | Helper virus-free herpesvirus amplicon particles and uses thereof |
WO2004064765A2 (en) * | 2003-01-23 | 2004-08-05 | University Of Rochester | Herpesvirus amplicon particles |
GB0317511D0 (en) | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
CA2545152A1 (en) * | 2003-11-07 | 2005-05-26 | Howard J. Federoff | Compositions and methods of treating neurological diseases |
US20080095744A1 (en) * | 2004-11-02 | 2008-04-24 | Parker Jacqueline N | Methods and Compositions for Cytokine Expression and Treatment of Tumors |
EP1903873A4 (en) * | 2005-06-03 | 2010-06-23 | Univ Rochester | HERPTIC VIRUS COMPOSITIONS AND METHODS OF USE IN PRENATAL AND PERINATAL PERIODS |
EP1904112A2 (en) * | 2005-06-03 | 2008-04-02 | The University Of Rochester | Herpes virus-based compositions and methods of use |
US20110039916A1 (en) * | 2006-06-06 | 2011-02-17 | University Of Rochester | Helper Virus-Free Herpesvirus Amplicon Particles and Uses Thereof |
CA2690627C (en) | 2007-06-15 | 2014-12-02 | Genelux Corporation | Microorganisms for imaging and/or treatment of tumors |
US8257712B2 (en) * | 2008-07-03 | 2012-09-04 | Saint Louis University | Virus-expressing host costimulation molecules |
EP3638205A4 (en) | 2017-06-14 | 2021-03-17 | Semma Therapeutics, Inc. | DEVICES AND METHODS FOR ADMINISTERING THERAPEUTICS |
BR112020009275A2 (pt) | 2017-11-15 | 2020-10-27 | Semma Therapeutics, Inc. | composições de fabricação de célula de ilhota e métodos de uso |
EP3758719A4 (en) * | 2018-03-02 | 2021-12-08 | Vertex Pharmaceuticals Inc. | METHODS FOR IMPROVING THE DIFFERENTIATION OF STEM CELLS INTO BETA CELLS |
EP3833365A4 (en) | 2018-08-10 | 2022-05-11 | Vertex Pharmaceuticals Incorporated | ISLE DIFFERENTIATION DERIVED FROM STEM CELLS |
AU2019362029A1 (en) * | 2018-10-19 | 2021-04-01 | University Of Rochester | Immune modulators in combination with radiation treatment for advanced pancreatic cancer |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2725091A (en) * | 1949-10-19 | 1955-11-29 | Us Rubber Co | Apparatus for joining thermoplastic sheet material |
US3661683A (en) * | 1970-11-03 | 1972-05-09 | Airline Systems Inc | Patch press |
US3837965A (en) * | 1972-10-17 | 1974-09-24 | Us Air Force | Portable repair apparatus |
US3996091A (en) * | 1974-09-11 | 1976-12-07 | General Electric Company | Method and apparatus for heat bonding |
US4745180A (en) * | 1986-06-27 | 1988-05-17 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using heparin fragments |
US5442156A (en) * | 1991-04-09 | 1995-08-15 | The Boeing Company | Heating apparatus for composite structure repair |
US5374388A (en) * | 1993-04-22 | 1994-12-20 | Lockheed Corporation | Method of forming contoured repair patches |
US5763217A (en) * | 1993-11-10 | 1998-06-09 | University Of British Columbia | Method of using, process of preparing and composition comprising recombinant herpesvirus vectors |
US5585096A (en) * | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5641665A (en) * | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
US5657972A (en) * | 1994-12-22 | 1997-08-19 | Isi Norgren, Inc. | Clamp with inflatable bladder |
JPH11502222A (ja) * | 1995-03-23 | 1999-02-23 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 遺伝子供給用ベクター |
WO1997000085A1 (en) * | 1995-06-19 | 1997-01-03 | University Of Medicine & Dentistry Of New Jersey | Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins |
US6344445B1 (en) * | 1995-10-19 | 2002-02-05 | Cantab Pharmaceutical Research Limited | Herpes virus vectors and their uses |
US5728258A (en) * | 1995-12-15 | 1998-03-17 | E-Systems, Inc. | Portable non-gravitational positive pressure generator and method of use |
US5975183A (en) * | 1998-03-23 | 1999-11-02 | Northrop Grumman Corporation | Repair pressure applicator for in the field damaged aircraft |
-
1998
- 1998-01-20 US US09/045,476 patent/US6051428A/en not_active Expired - Fee Related
- 1998-03-20 EP EP98920820A patent/EP0968299A1/en not_active Withdrawn
- 1998-03-20 AU AU73570/98A patent/AU7357098A/en not_active Abandoned
- 1998-03-20 CA CA002287156A patent/CA2287156A1/en not_active Abandoned
- 1998-03-20 WO PCT/US1998/005505 patent/WO1998042855A1/en not_active Application Discontinuation
- 1998-03-20 JP JP54583098A patent/JP2002511846A/ja not_active Ceased
-
2003
- 2003-03-24 US US10/470,568 patent/US20040157299A1/en not_active Abandoned
- 2003-06-16 US US10/463,319 patent/US20040047837A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6051428A (en) | 2000-04-18 |
AU7357098A (en) | 1998-10-20 |
WO1998042855A1 (en) | 1998-10-01 |
EP0968299A1 (en) | 2000-01-05 |
CA2287156A1 (en) | 1998-10-01 |
US20040157299A1 (en) | 2004-08-12 |
US20040047837A1 (en) | 2004-03-11 |
WO1998042855A9 (en) | 1999-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002511846A (ja) | Hsvアンプリコンベクターによる自家腫瘍ワクチンの迅速な産生 | |
US6350445B1 (en) | Method of treating cancer with a tumor cell line having modified cytokine expression | |
Schmidt et al. | Cancer vaccines: the interleukin 2 dosage effect. | |
Toda et al. | In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity | |
US6277368B1 (en) | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine | |
CA2263503C (en) | Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same | |
Yamanaka et al. | Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus—mediated interleukin-12 | |
JP2012067114A (ja) | 腫瘍治療を目的とするヘルペスベクターの使用 | |
AU675948B2 (en) | Bystander effect tumoricidal therapy | |
JP2002524537A (ja) | サイトカイン発現が遺伝的に増強された抗原提示細胞のインサイチュ注入 | |
JP2011036251A (ja) | ウイルスベクターおよびその遺伝子治療のための使用 | |
Zhang et al. | Tumour necrosis factor‐α (TNF‐α) transgene‐expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T‐cell activation and anti‐tumour immunity than DCs generated in recombinant TNF‐α | |
JPH10505339A (ja) | 腫瘍疾患の治療のための生ワクチン | |
Moran et al. | Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice | |
Davidoff et al. | Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12 | |
JP2004026802A (ja) | 人間あるいは動物体内の癌あるいは腫瘍を治療する薬物を製造する方法 | |
JP2003514522A (ja) | 樹状細胞の微粒子ベースのトランスフェクションおよび活性化 | |
JP4423508B2 (ja) | 癌遺伝子治療薬 | |
Esandi et al. | IL-1/IL-3 gene therapy of non-small cell lung cancer (NSCLC) in rats using ‘cracked’adenoproducer cells | |
US7064111B1 (en) | Use of soluble costimulatory factor for tumor immuno-gene therapy | |
Coukos et al. | Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm | |
US6087174A (en) | Growth medium for primary pancreatic tumor cell culture | |
EP0834323A1 (en) | Cytokine gene therapy for treatment of malignacies | |
JP2000505284A (ja) | 形質導入されたヒト造血幹細胞 | |
Lander et al. | Development and in vitro characterization of a GM-CSF secreting human ovarian carcinoma tumor vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080806 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080818 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080912 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091110 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20100301 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100406 |